Covid-19: What is the evidence for the antiviral molnupiravir? | The BMJ Skip to main content
Intended for healthcare professionals Access provided by Google Indexer Subscribe My …

Abstract Molnupiravir (MK‐4482) is an oral prodrug of the antiviral ribonucleoside analog, N‐
hydroxycytidine (NHC), which has activity against RNA viruses, including severe acute …

Background Clinical benefit of molnupiravir (MPV) in coronavirus disease 2019 (COVID-19)–
infected subpopulations is unclear. Methods We used a matched cohort study design to …

Introduction An outbreak of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
was reported in Wuhan, China, in mid-December 2019, and declared a pandemic by the …

Background Using a retrospective cohort study design, we aimed to evaluate the
effectiveness of molnupiravir and nirmatrelvir/ritonavir in patients with SARS-CoV-2 who …

This meta-analysis was conducted with the aim to assess the safety and efficacy of
favipiravir in treating patients with coronavirus disease 2019 (COVID-19). It was carried out …

Molnupiravir has been the first oral antiviral authorized for COVID-19 outpatients, reporting
extraordinary sales and preserved in vitro efficacy against Omicron sublineages so far …

Objectives To evaluate the efficacy and safety of molnupiravir for intra-household post-
exposure prophylaxis (PEP) of COVID-19. Methods MOVe-AHEAD was a randomized …

Objectives This study aimed to evaluate the efficacy and adverse events of favipiravir in
patients with COVID-19. Methods Our protocol was registered on PROSPERO …

On 4 th November 2021, the first oral antiviral drug for COVID-19, molnupiravir (Lagevrio®),
received full regulatory approval from the Medicines and Healthcare Products Regulatory …